What is the recommended initiation, dosing, and monitoring of mexiletine for symptomatic myotonia in an adult with myotonic dystrophy type 1 without severe cardiac conduction abnormalities?

Mexiletine for Myotonic Dystrophy Type 1

Mexiletine is effective and safe for treating symptomatic myotonia in adults with myotonic dystrophy type 1 (DM1) who lack severe cardiac conduction abnormalities, with initiation at 200 mg three times daily, titrated based on response while maintaining rigorous cardiac monitoring throughout treatment. 1, 2

Initiation Protocol

Pre-Treatment Cardiac Assessment

Before starting mexiletine, exclude severe conduction abnormalities that would contraindicate therapy 3, 4:

• Contraindications include: PR interval ≥230 ms, complete bundle branch block, atrial fibrillation, or advanced AV block 4
• Obtain baseline ECG and 24-hour Holter monitoring 3, 5
• Document baseline PR interval, QRS duration, and QTc interval 5

Starting Dose

Begin with 200 mg three times daily (600 mg total daily dose) taken with food or antacid 1, 2. The FDA label recommends this as the standard starting dose when rapid arrhythmia control is not needed 1.

For patients requiring faster symptom control, a loading dose of 400 mg followed by 200 mg eight hours later may be used, though this is primarily described for cardiac arrhythmias 1.

Dose Titration

Adjust dosage in 50-100 mg increments every 2-3 days based on clinical response and tolerance 1:

• Most patients achieve satisfactory control at 200-300 mg three times daily 1
• Maximum dose: 400 mg three times daily (1200 mg/day total) 1
• Italian expert consensus suggests typical maintenance doses of 100-600 mg daily for DM patients, though this is lower than FDA recommendations 6

The evidence shows mexiletine at both 150 mg and 200 mg three times daily effectively reduces grip myotonia over 7 weeks 2, though higher doses may be needed for sustained benefit.

Cardiac Monitoring Requirements

DM1 patients require more intensive cardiac surveillance than non-dystrophic myotonia patients due to progressive conduction disease 3:

During Titration

• ECG at each dose adjustment 3
• Monitor for PR interval prolongation, QRS widening, or QTc changes 5

Long-Term Monitoring

• ECG every 3 months during the first year 3
• 24-hour Holter monitoring every 6 months 3
• Annual comprehensive cardiac evaluation including echocardiography 3

Reassuringly, studies show mexiletine 200 mg twice daily does not accelerate conduction delay or increase bradyarrhythmic complications requiring pacemaker implantation over median 53-month follow-up 4. Similarly, no clinically significant changes in PR, QRS, or QTc intervals occurred over 6 months in controlled trials 5.

Expected Clinical Outcomes

Efficacy

Mexiletine significantly improves objective myotonia measures but shows variable effects on functional outcomes 5, 2, 7:

• Hand grip relaxation time improves by 1.37 seconds (moderate-certainty evidence) 7
• 96% of patients report subjective improvement in myotonia symptoms with long-term use 8
• No significant improvement in 6-minute walk distance at 6 months 5
• Quality of life measures show inconsistent results in DM1 patients 5, 7

The disconnect between objective myotonia improvement and functional outcomes suggests mexiletine treats the symptom but does not address underlying muscle weakness or other DM1 manifestations 5.

Safety Profile

Mexiletine is well-tolerated with predominantly mild adverse effects 2, 4, 8:

Common Side Effects

• Gastrointestinal symptoms (nausea, dyspepsia) 2, 7
• Lethargy and fatigue 7
• Headache 7
• Tremor 2

Serious Adverse Events

No clinically relevant cardiac adverse events occurred in long-term studies (mean 32.9 months) 8. Importantly, class I antiarrhythmic agents can theoretically increase peripheral muscle weakness, though this was not observed in DM1 trials 9.

Drug Interactions

Mexiletine metabolism involves CYP2D6 and CYP1A2 enzymes 10:

• The CYP2D6*2/*41 diplotype associates with non-response (11 times more frequent in non-responders) 10
• Concomitant medications affecting these enzymes may alter mexiletine levels 1
• Patients with severe liver disease or marked right-sided heart failure require dose reduction 1

Critical Caveats

Cardiac Risk in DM1

Approximately 80% of DM1 patients develop cardiac manifestations, with progressive conduction defects and arrhythmias being the most life-threatening complications 9. Respiratory complications and cardiac arrhythmias are the most frequent causes of death 9. This mandates the enhanced cardiac surveillance protocol outlined above, which exceeds monitoring requirements for non-dystrophic myotonia patients 3.

Non-Responders

Approximately 26% of patients do not respond adequately to mexiletine 10. Genetic factors, particularly CYP2D6 polymorphisms, may predict treatment response 10. For non-responders, alternative agents like lamotrigine may be considered, though evidence is limited 7.

Availability Issues

Mexiletine production has been problematic in some countries (e.g., Italy in 2022), potentially limiting access 6. Clinicians should verify local availability before initiating treatment.